UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024
Revenues:
Finance receivable interest income, including fees	$ 8,543	$ 9,986	$ 19,255	$ 21,021
Pharmaceutical development	1,190	804	2,153	1,083
Other	319	57	476	103
Total revenues	10,052	10,847	21,884	22,207
Costs and expenses:
Provision (benefit) for credit losses	761	4,095	(704)	9,392
Loss on impairment of intangibles assets	0	5,771	0	5,771
Interest expense	1,155	1,119	2,285	2,375
Pharmaceutical manufacturing, research and development expense	645	520	1,403	1,050
Change in fair value of acquisition-related contingent consideration	0	(4,900)	0	(4,900)
Depreciation and amortization expense	19	421	38	935
General and administrative expense	2,843	2,920	6,120	5,604
Income from operations	4,629	901	12,742	1,980
Other income (expense), net
Unrealized net gain (loss) on warrants	347	226	(77)	131
Net gain on exercise and cancellation of warrants	0	675	0	444
Loss on sale of assets	0	0	(82)	0
Net gain (loss) on marketable investments	37	(19)	(68)	(162)
Realized gain on early payment of finance receivable	0	0	1,729	0
Gain (loss) on revaluation of finance receivables	0	2,495	(3,727)	2,495
Realized and unrealized foreign currency transaction gains (losses)	(451)	437	(138)	524
Income before income tax expense	4,562	4,715	10,379	5,412
Income tax expense	1,026	1,035	2,304	1,264
Net income	$ 3,536	$ 3,680	$ 8,075	$ 4,148
Net income per share
Basic (in dollars per share)	$ 0.29	$ 0.30	$ 0.66	$ 0.33
Diluted (in dollars per share)	$ 0.29	$ 0.30	$ 0.66	$ 0.33
Weighted average shares outstanding
Basic (in shares)	12,208,000	12,458,000	12,218,000	12,467,000
Diluted (in shares)	12,208,000	12,470,000	12,218,000	12,484,000